SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network is facing intense community scrutiny following a significant price decline, with many users reporting difficulty executing trades amid platform maintenance. While some investors are concerned about potential volatility, others are debating the project's long-term utility in enterprise infrastructure and cloud computing.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently driven by heightened anticipation surrounding upcoming clinical data presentations at the Society for Investigative Dermatology and other healthcare conferences. The community is actively debating the company's potential for high-impact oncology and autoimmune treatments, while retail traders closely monitor significant institutional buying and a heavy short interest that some believe sets the stage for a potential squeeze.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool Corp. is facing significant volatility following a weak earnings report that featured a revenue miss, a surprise loss, and the suspension of its dividend to address debt. While some investors view the stock's multi-year lows as a long-term value play supported by potential tariff tailwinds, the community remains heavily divided over management's performance and the company's ability to navigate a challenging housing and consumer spending environment.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing renewed investor interest and volatility as the community monitors its inclusion in the Russell 2000 Index and potential opportunities within the defense and aerospace sectors. Traders remain deeply divided, with some betting on a rebound supported by mission-critical hardware contracts and technical setups, while others caution against the stock's high volatility and aggressive price fluctuations.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo is currently a focal point for investors due to its role as the exclusive custodian for World Liberty Financial, which recently received conditional federal approval, alongside intense market debate over the company's valuation and the effectiveness of its share buyback program. While some market participants anticipate a short squeeze fueled by significant institutional accumulation and technical support, others remain skeptical, citing persistent regulatory uncertainty and comparisons to previous underperforming crypto IPOs.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis Inc - Ordinary Shares - Class A

Zoetis is trending as investors weigh strong earnings performance and raised guidance against ongoing volatility in the animal health sector. The community is actively debating the company's long-term competitive moat and the impact of its innovative product pipeline on future growth.

Anthropic

Anthropic is trending as it accelerates toward a potential massive IPO this fall, fueled by a 14-fold surge in revenue and a competitive race for enterprise AI dominance. The community is actively debating the company's valuation projections alongside high-stakes partnerships and infrastructure deals that solidify its position as a primary challenger to OpenAI.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is attracting significant attention as investors shift focus toward decentralized infrastructure and AI-native cloud computing, with the community actively debating the long-term impact of its 'Cloud Engines' and 'Caffeine' AI-agent tools. While some participants express frustration over historical volatility and tokenomics, many are increasingly bullish, citing ICP's potential to replace centralized providers like AWS and pointing to its growing adoption in government and enterprise pilots as signs that the technology is maturing beyond pure speculation.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense bearish pressure as the community debates whether the token is a deep-value opportunity for a long-term cycle recovery or a fundamentally broken project nearing its bottom. Investors are actively discussing the lack of buying volume, concerns over tokenomics and inflation, and the stark contrast between the project's real-world institutional adoption and its weak price performance.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is trending as investors debate the company's long-term pivot toward autonomous laboratory infrastructure following the rollout of new AI-integrated cloud lab capabilities. While bulls are highlighting the platform's potential as a foundational layer for synthetic biology, bears continue to express deep skepticism over significant cash burn and a lack of consistent revenue growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cancer Stocks That Are Advancing the Future of Oncology Care

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Wall Street Zen raised Xilio Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8% - What's Next?

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 4.8% - What's Next...

Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened

Xilio Therapeutics (NASDAQ:XLO) Sees Strong Trading Volume - Here's Why...

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

XLOXilio Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest XLO News